Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
WilmerHale advised the underwriters in the
public offering of 16,203,500 shares of common stock of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), at a public offering price of $35.50 per share, including the full exercise of the underwriters’ option to purchase an additional 2,113,500 shares of common stock. Amylyx is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. Total gross proceeds from the offering, including the exercise of the underwriters’ option to purchase additional shares, were approximately $575 million, excluding underwriting discounts, commissions and other offering-related expenses. The offering priced on August 19, 2026, and closed on August 21, 2026.
The WilmerHale team was led by
Lisa Firenze and included
Hilary Baker-Jennings,
Amy O’Connell and
Sophie Bonadeo, with assistance from
Barish Ozdamar on intellectual property matters,
George O’Brien on regulatory matters, and
Meghan Walsh on tax matters.
